DiscoveryProbe™ FDA-approved Drug Library: Comprehensive High-Throughput Screening Resource for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 clinically validated bioactive compounds, approved or listed by global regulatory agencies, pre-dissolved at 10 mM in DMSO for immediate use. The collection enables high-throughput (HTS) and high-content screening (HCS), facilitating rapid drug repositioning and pharmacological target identification across diverse disease models, including cancer and neurodegeneration (Li et al., 2024). Representative drugs target mechanisms such as receptor modulation, enzyme inhibition, ion channel regulation, and signaling pathway interference. Compounds remain stable for 12 months at −20°C and 24 months at −80°C, supporting reproducible research. APExBIO provides flexible formats (96-well/deep well plates, 2D barcoded tubes), ensuring compatibility with automated workflows.

Biological Rationale

Drug repositioning accelerates the identification of new therapeutic uses for existing, clinically approved drugs, reducing development timelines and safety risks compared to de novo discovery (see LB Broth Miller 2022). The DiscoveryProbe™ FDA-approved Drug Library addresses the need for a systematic, high-throughput approach to screen bioactive molecules with known pharmacokinetics, safety, and mechanisms. Many human diseases, such as cancer, neurodegenerative disorders, and inflammatory conditions, share common signaling pathways modulated by FDA-approved drugs (Li et al., 2024). Leveraging these compounds accelerates the discovery of previously unrecognized therapeutic targets and mechanistic insights. Validated compound libraries also serve as reference standards for benchmarking new screening platforms and for functional pathway validation.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains molecules with well-characterized and diverse mechanisms of action. These include:

• Receptor agonists and antagonists: Drugs modulate GPCRs, nuclear hormone receptors, and ion channels (e.g., metformin for AMPK, doxorubicin for Topoisomerase II).
• Enzyme inhibitors: Compounds inhibit kinases (e.g., saracatinib, which targets MLKL in necroptosis), proteases, and metabolic enzymes (Li et al., 2024; see also DOI).
• Ion channel modulators: Agents affecting calcium, potassium, or sodium channels, relevant in neurological and cardiovascular research.
• Signal pathway regulators: Compounds perturb NF-κB, MAPK, and PI3K/AKT/mTOR pathways, commonly dysregulated in disease.
• Epigenetic modifiers: Some agents alter DNA methylation or histone acetylation, expanding applications in cancer and developmental biology.

Each compound is annotated with regulatory approval status, primary and secondary targets, and, where available, structure-activity relationships. This mechanistic diversity underpins the library’s utility in screening for both intended and off-target effects, supporting hypothesis-driven and unbiased discovery approaches (see Pentynoic Acid STP Ester 2022; extends mechanism details).

Evidence & Benchmarks

• In a mouse model of imiquimod-induced psoriasis, screening a small-molecule compound library identified saracatinib as an inhibitor of TNF-induced necroptosis via direct targeting of MLKL (Li et al., 2024, https://doi.org/10.1038/s41419-024-06514-y).
• DiscoveryProbe™ FDA-approved Drug Library compounds are stable at −20°C for 12 months and at −80°C for 24 months in DMSO (APExBIO product documentation, product page).
• The library enables reproducible high-throughput screening (HTS) and high-content screening (HCS) workflows for target identification in oncology and neurodegeneration (LB Broth Miller 2022, https://lb-broth-miller.com).
• Compounds are pre-dissolved at 10 mM in DMSO and provided in 96-well or deep well plates, or 2D barcoded tubes, supporting automated liquid handling (APExBIO, product page).
• Drug repositioning screens using FDA-approved libraries have successfully identified novel indications for kinase inhibitors, antidiabetics, and statins, demonstrating the translational impact of such resources (BMS-509744 2022, https://bms-509744.com).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is utilized in a broad array of research domains:

• Cancer research drug screening: Enables pathway-focused and phenotypic screens to identify anti-tumor agents or resistance modulators.
• Neurodegenerative disease drug discovery: Facilitates the identification of compounds modulating neuroinflammatory, synaptic, or metabolic pathways.
• Signal pathway regulation studies: Supports mapping of drug-pathway interactions and discovery of off-target effects.
• Enzyme inhibitor screening: Rapidly identifies inhibitors of disease-relevant kinases, proteases, or metabolic enzymes.
• Drug repositioning screening: Finds new therapeutic indications for established drugs, reducing translational risk and development time.
• High-content and high-throughput profiling: Compatible with multiplexed phenotypic assays and large-scale target deconvolution.

For nuanced discussion of integration strategies and evidence, see this overview, which our article extends by providing atomic claims and new mechanistic benchmarks from recent peer-reviewed studies.

Common Pitfalls or Misconceptions

• The library is not suitable for direct use in clinical settings; it is a research-use-only (RUO) product.
• Not all compounds are selective for single targets; polypharmacology is common and should be accounted for in interpretation.
• Compound concentration (10 mM stock) requires dilution; excessive DMSO (>0.5% v/v) can introduce cytotoxicity in cell-based assays.
• The collection does not cover all experimental disease models; some orphan targets or rare pathways may be underrepresented.
• Regulatory approvals listed refer to the original clinical indication; new uses require independent validation and regulatory review.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is formatted for seamless integration into automated screening pipelines. Key workflow parameters include:

• Format: 96-well or deep well plates, and 2D barcoded screw-top storage tubes, compatible with robotic liquid handlers.
• Storage: −20°C (12 months) or −80°C (24 months) for optimal stability.
• Compound concentration: 10 mM in DMSO; typical working concentrations range from 0.1–10 μM after dilution.
• Shipping: Evaluation samples on blue ice; other sizes at room temperature or blue ice on request.
• Data integration: Each compound is annotated with regulatory status, mechanism, and structure, supporting bioinformatics workflows.
• Quality control: Each batch is subjected to LC-MS and HPLC analysis, confirming identity and purity (>95%).

For advanced experimental design and integration with time-resolved proteomics or cellular heterogeneity studies, see our extended roadmap—this article updates prior strategies with new evidence from necroptosis screening.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO provides a robust, versatile resource for translational drug discovery. By leveraging clinically validated, mechanistically diverse compounds, the library accelerates target identification, drug repositioning, and pathway analysis in both academic and industrial settings. Ongoing integration with phenotypic screening, multi-omics, and AI-driven target deconvolution will further enhance its translational impact. For detailed protocols, compound lists, and ordering information, refer to the official product page.